Cost-utility Analysis of Toripalimab Plus Axitinib in the First-line Treatment of Advanced Renal Cell Carcinoma
10.3870/j.issn.1004-0781.2025.06.021
- VernacularTitle:特瑞普利单抗联合阿昔替尼一线治疗晚期肾细胞癌的成本-效果分析
- Author:
Hao CHEN
1
;
Shixian LIU
1
;
Shunping LI
1
;
Lei DOU
1
;
Zehua SONG
1
Author Information
1. 山东大学齐鲁医学院公共卫生学院卫生管理与政策研究中心,济南 250012;国家卫生健康委员会卫生经济与政策研究重点实验室(山东大学),济南 250012;山东大学健康偏好研究中心,济南 250012
- Publication Type:Journal Article
- Keywords:
Toripalimab;
Sunitinib;
Advanced renal cell carcinoma;
Cost-utility analysis;
Partitioned survival model
- From:
Herald of Medicine
2025;44(6):965-972
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the cost-effectiveness of toripalimab plus axitinib compared to sunitinib in the first-line treatment of advanced renal cell carcinoma patients.Methods Based on the RENOTORCH trial,constructed a partitioned survival model to evaluate the long-term costs and health outcomes of toripalimab plus axitiniband sunitinib in the first-line treatment of advanced renal cell carcinoma(RCC)patients from the Chinese healthcare system perspective.The cycle length of the model was 3weeks,simulating the total cost,quality adjusted life years(QALYs),and incremental cost-effectiveness ratio(ICUR)for patients over 25 years.The costs were derived from the average bidding price of Yaozhi database in 2023 and published literature.The health state utility values were derived from clinical trials.The discount rate was 5%,and the willingness to pay(WTP)threshold was 3 times the per capita gross domestic product(GDP)in 2022.One-way and probability sensitivity analyses were used to test the robustness of the model.Results Based on the progression free survival(PFS)evaluated by the Independent Review Committee(IRC)and Investigator(IA),the ICUR values were 239 436.39 yuan/QALY and 175 440.39 yuan/QALY,respectively,both lower than the WTP threshold.One-way sensitivity analysis showed that the health state utility values of PFS status and the price of axitinib had a significant impact on the model.Probability sensitivity analysis showed that the probability of toripalimab plus axitinib being cost-effective was 63.64%and 98.03%according to the IRC and IA assessments,respectively.Conclusion Toripalimab plus axitinib was cost-effective in the first-line treatment of advanced RCC patients.
